stockrow
Friday 6 November 2026
Export BIO’s income statement to Excel — free account
Bio-Rad Laboratories, Inc.
BIO Healthcare Medical Devices
Bio-Rad Laboratories, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.6 billion, up 0.65% from fiscal 2024.
- Revenue
- +0.52%
- EPS
- +234.8%
- Free cash flow
- +8.07%
- Total debt
- +0.11%
Quarter to September 2026, against a year earlier
382.51
13.51
+3.66%
Follow BIO
Alert me
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
190.53 | 62.54 | 19.07 | 6.28 | 4.56 | 5.30 | 0.00 | 0.00 | 0.00 | 10.84 |
Piotroski F-Score |
4 | 5 | 5 | 5 | 7 | 3 | 4 | 6 | 6 | 5 |
P/S ratio |
2.60 | 3.31 | 3.03 | 4.78 | 6.82 | 7.71 | 4.49 | 3.59 | 3.61 | 3.20 |
Altman Z-Score |
4.21 | 4.77 | 4.23 | 4.47 | 4.81 | 4.70 | 3.52 | 3.20 | 3.80 | 3.20 |
P/FCF ratio |
71.96 | 0.00 | 43.31 | 29.98 | 36.16 | 41.80 | 150.12 | 43.46 | 31.77 | 21.93 |
Altman Z″-Score (non-manufacturers) |
6.12 | 6.14 | 6.53 | 6.14 | 6.66 | 6.64 | 6.49 | 6.57 | 7.04 | 6.54 |
Beneish M-Score |
(2.77) | (2.18) | (2.32) | (1.55) | (0.99) | (1.40) | (4.47) | (2.89) | (3.84) | (2.29) |
P/Operating CF |
56.83 | 103.25 | 65.98 | 69.10 | 58.95 | 131.91 | 158.05 | 118.27 | 74.63 | 50.09 |
P/B ratio |
2.09 | 2.44 | 1.72 | 1.92 | 1.76 | 1.65 | 1.31 | 1.10 | 1.41 | 1.11 |
Price to Tangible BV |
2.78 | 3.18 | 1.89 | 2.07 | 1.85 | 1.72 | 1.42 | 1.20 | 1.58 | 1.23 |
EV/Sales |
2.41 | 3.16 | 2.85 | 4.48 | 6.43 | 7.42 | 4.28 | 3.43 | 3.43 | 3.07 |
EV/EBITDA |
29.99 | 30.34 | 0.00 | 45.12 | 38.85 | 43.32 | 24.83 | 27.14 | 32.73 | 167.85 |
EV/Operating CF |
23.03 | 65.62 | 22.83 | 22.63 | 27.98 | 32.38 | 61.65 | 24.45 | 19.34 | 14.89 |
EV/FCF |
66.48 | (619.06) | 40.74 | 28.13 | 34.11 | 40.20 | 142.98 | 41.59 | 30.19 | 21.03 |
Quick Ratio |
2.58 | 2.44 | 2.76 | 1.67 | 2.24 | 1.91 | 4.03 | 4.02 | 4.53 | 3.87 |
Current Ratio |
3.91 | 3.93 | 4.49 | 2.41 | 3.39 | 2.92 | 5.55 | 5.83 | 6.48 | 5.62 |
Net Debt/EBITDA |
(7.36) | (2.73) | 3.98 | (2.96) | (2.33) | (1.73) | (1.24) | (1.22) | (1.72) | (7.15) |
Debt/Assets |
11.28% | 10.18% | 7.83% | 5.49% | 0.11% | 0.06% | 8.87% | 9.75% | 12.83% | 11.37% |
Debt/Equity |
0.17 | 0.15 | 0.11 | 0.08 | 0.00 | 0.00 | 0.12 | 0.14 | 0.18 | 0.16 |
Asset Turnover |
0.55 | 0.53 | 0.46 | 0.34 | 0.24 | 0.19 | 0.18 | 0.21 | 0.24 | 0.26 |
Operating CF/Net income |
8.31 | 0.85 | 0.78 | 0.26 | 0.15 | 0.16 | (0.05) | (0.59) | (0.25) | 0.70 |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Interest Coverage |
2.38 | 5.18 | (4.31) | 9.81 | 19.27 | 322.59 | 12.67 | 6.84 | 5.50 | 0.96 |
| 1.03% | 4.44% | 10.52% | 35.98% | 48.79% | 36.11% | (31.14%) | (6.94%) | (24.09%) | 10.84% | |
| 0.69% | 3.01% | 7.40% | 25.83% | 36.36% | 27.65% | (23.18%) | (4.94%) | (17.03%) | 7.62% | |
ROIC |
1.61% | 2.86% | (1.79%) | 2.83% | 2.96% | 2.44% | 3.34% | 2.54% | 2.75% | 0.41% |
Return on Tangible Assets |
1.40% | 6.21% | 17.57% | 99.14% | 190.74% | 233.60% | (117.48%) | (20.86%) | (59.67%) | 25.94% |
Average Days of Receivables |
65.71 | 78.55 | 62.57 | 62.00 | 60.14 | 52.90 | 64.43 | 66.82 | 64.35 | 65.08 |
Research and Development Expense of Revenue |
9.95% | 11.58% | 8.70% | 8.77% | 8.55% | 8.92% | 0.00% | 0.00% | 11.53% | 10.67% |
Selling, General and Administrative Expense of Revenue |
39.39% | 37.35% | 36.46% | 35.67% | 31.38% | 30.01% | 29.54% | 31.51% | 31.72% | 32.68% |
Intangible Assets out of Total Assets |
0.17 | 0.16 | 0.06 | 0.05 | 0.04 | 0.03 | 0.05 | 0.06 | 0.08 | 0.07 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 2.25% |
Graham Net Nets |
0.11 | 0.09 | 0.06 | (0.01) | (0.05) | (0.09) | (0.06) | (0.05) | 0.03 | (0.03) |
Graham Number |
43.50 | 92.64 | 192.17 | 505.67 | 977.42 | 1,213.40 | 0.00 | 0.00 | 0.00 | 414.65 |
Earnings Yield |
0.52% | 1.60% | 5.25% | 15.93% | 21.95% | 18.88% | (28.72%) | (6.54%) | (19.79%) | 9.22% |
Free Cash Flow Yield |
1.39% | (0.15%) | 2.31% | 3.34% | 2.77% | 2.39% | 0.67% | 2.30% | 3.15% | 4.56% |
Revenue per Share |
70.25 | 72.84 | 76.73 | 77.46 | 85.52 | 97.97 | 94.08 | 91.45 | 90.97 | 94.75 |
Operating CF per Share |
7.34 | 3.51 | 9.57 | 15.34 | 19.65 | 22.44 | 6.53 | 12.84 | 16.13 | 19.52 |
Capex per Share |
(4.80) | (3.88) | (4.21) | (3.00) | (3.53) | (4.48) | (3.83) | (5.36) | (5.87) | (5.78) |
Free Cash Flow per Share |
2.54 | (0.37) | 5.36 | 12.34 | 16.12 | 17.96 | 2.70 | 7.48 | 10.27 | 13.74 |
Cash per Share |
28.67 | 25.65 | 28.50 | 37.54 | 33.48 | 29.35 | 60.31 | 55.21 | 59.00 | 56.51 |
Shareholders Equity per Share |
87.61 | 98.81 | 134.75 | 192.84 | 331.90 | 458.76 | 322.82 | 299.26 | 232.84 | 273.40 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
87.61 | 98.81 | 134.75 | 192.84 | 331.90 | 458.76 | 322.82 | 299.26 | 232.84 | 273.40 |
Free Cash Flow |
74.89 | (10.90) | 159.98 | 368.31 | 479.89 | 535.77 | 80.30 | 218.40 | 289.70 | 374.70 |
Working Capital |
1,373.20 | 1,473.95 | 1,572.68 | 1,274.66 | 1,508.30 | 1,309.54 | 2,589.27 | 2,525.50 | 2,562.50 | 2,389.20 |
Capital Expenditures |
(141.17) | (115.04) | (125.51) | (89.58) | (105.08) | (133.69) | (114.10) | (156.50) | (165.50) | (157.50) |
Net Current Asset Value |
573.18 | 633.89 | 432.74 | (73.65) | (952.84) | (2,123.68) | (728.44) | (509.60) | 235.50 | (216.70) |
EV/EBIT |
89.30 | 57.31 | 0.00 | 45.12 | 38.85 | 43.32 | 24.83 | 27.14 | 32.73 | 167.85 |
Capex to Sales |
0.07 | 0.05 | 0.05 | 0.04 | 0.04 | 0.05 | 0.04 | 0.06 | 0.06 | 0.06 |
Price to Operating Income |
96.65 | 60.04 | 0.00 | 48.08 | 41.19 | 45.05 | 26.07 | 28.36 | 34.46 | 175.01 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cash ROIC |
1.94% | (0.26%) | 3.01% | 5.04% | 4.41% | 3.68% | 0.64% | 1.89% | 3.07% | 3.67% |
Accounts Receivable Turnover |
5.42 | 5.16 | 5.34 | 5.89 | 6.27 | 6.93 | 6.10 | 5.43 | 5.45 | 5.66 |
Accounts Payable Turnover |
7.28 | 7.25 | 8.28 | 9.19 | 8.99 | 9.13 | 8.92 | 8.90 | 8.90 | 9.89 |
Inventory Turnover |
1.83 | 1.74 | 1.81 | 1.85 | 1.88 | 2.15 | 1.91 | 1.66 | 1.54 | 1.66 |
Average Days of Payables |
52.26 | 50.74 | 41.92 | 37.04 | 45.95 | 40.34 | 39.91 | 42.42 | 37.59 | 37.87 |
Days of Inventory on Hand |
206.09 | 223.25 | 199.85 | 191.73 | 205.03 | 162.61 | 212.61 | 228.95 | 233.58 | 217.45 |
Average Receivables |
381.92 | 418.60 | 428.65 | 392.56 | 406.05 | 421.48 | 459.09 | 491.82 | 470.75 | 456.55 |
Average Payables |
127.75 | 134.15 | 128.82 | 114.73 | 123.23 | 140.70 | 138.49 | 139.82 | 133.45 | 125.65 |
Average Inventory |
507.59 | 559.88 | 589.31 | 568.91 | 588.13 | 597.25 | 645.78 | 749.91 | 770.25 | 750.35 |
Average Assets |
3,780.11 | 4,061.76 | 4,942.04 | 6,809.96 | 10,490.74 | 15,386.01 | 15,650.53 | 12,900.39 | 10,831.60 | 9,970.30 |
Average Common Equity |
2,534.83 | 2,754.71 | 3,475.29 | 4,887.69 | 7,817.50 | 11,782.59 | 11,650.25 | 9,178.23 | 7,655.25 | 7,011.45 |
Columns are period end dates · fundamentals updated 6 Nov 2026